Table: Kyowa Kirin -Q1 group results (IFRS)
May 7 (Reuters)-
Kyowa Kirin Co., Ltd.
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
3 months ended 3 months ended Year to
Mar 31, 2024 Mar 31, 2023 Dec 31, 2024
LATEST YEAR-AGO COMPANY
RESULTS RESULT FORECAST
Sales 105.57 93.54 473.00
(+12.9 pct) (+6.6 pct) (+7.0 pct)
Operating
Pretax 18.10 15.58 85.00
(+16.2 pct) (-16.7 pct) (-12.6 pct)
Net 14.63 12.76 63.00
(+14.7 pct) (-20.4 pct) (-22.4 pct)
EPS Basic 27.26 yen 23.74 yen 119.07 yen
EPS Diluted 27.26 yen 23.74 yen
Ann Div 56.00 yen 58.00 yen
-Q2 Div 27.00 yen 29.00 yen
-Q4 Div 29.00 yen 29.00 yen
NOTE - Kyowa Kirin Co., Ltd..
(Figures are reported based on international accounting rules (IFRS).)
If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half
dividend and Q4 to the second-half dividend announced before a new corporate law in
2006 allowed companies to pay and report dividends on a quarterly basis.
*Net - represents Net profit attributable to owners of the parent company.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4151.T
Recent news on Kyowa Kirin
See all newsFactbox: Global pharma companies that have publicly announced Trump drug pricing agreements
Factbox: Global pharma companies that have publicly announced Trump drug pricing agreements
Brief: Kyowa Kirin Announces Agreement With US Administration To Reduce Treatment Costs For Americans
Table: Kyowa Kirin 6-MTH group results (IFRS)
Brief: Kyowa Kirin Says European Commission Approves Crysvita For Infants With X-Linked Hypophosphataemia